Journal
FRONTIERS IN BIOSCIENCE
Volume 12, Issue -, Pages 3273-3286Publisher
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/2311
Keywords
prostate cancer; metastasis; bone; osteoblast; cancer stem cell; PSA; androgen deprivation therapy
Categories
Funding
- NCI NIH HHS [CA111479, P50-CA90270] Funding Source: Medline
Ask authors/readers for more resources
Prostate cancer is the most common cancer among men in the United States. Advanced prostate cancer has a particular propensity to metastasize to bone, where it produces predominantly osteoblastic lesions and local bone formation. The tropism for bone is thought to be due in part to specific interactions between the prostate cancer cells and cells present in the bone environment, particularly the bone marrow endothelial cells and osteoblasts. Such interactions involve numerous signaling pathways that could serve as targets for new therapeutic agents. Because androgen directly influences the proliferation and metastasis of prostate cancer cells, the current first-line treatment for metastatic prostate cancer is androgen deprivation therapy. Subsequent therapies include chemotherapy and radiation therapy. New molecular therapies are being developed to target specific steps in the metastatic process. However, as yet none of these therapies has radically improved survival. Nonetheless, it is hoped that with better understanding of the biology of the disease, combination therapy that addresses multiple pathways that support the progression of prostate cancer in bone could significantly improve the survival and quality of life of men with prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available